Patent SG-11201903178Q-A (SG)
Title: Anti-ceacam6 antibodies and methods of use
Inventor: LEUNG HAU WAN
IPC: C07K16/30
Filed: 2017-10-10
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 011111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/070936 Al 19 April 2018 (19.04.2018) WIP0 1 PCT (51) International Patent Classification: Centros, Singapore 138668 (SG). CHOO, Andre Boon C07K 16/30 (2006.01) G01N 33/574 (2006.01) Hwa; c/o Bioprocessing Technology Institute, 20 Biopo- A61K 39/395 (2006.01) A61P 35/00 (2006.01) Es Way, Level 4 (Stem Cells) Centros, Singapore 138668 (SG). DING, Mei Yee Vanessa; c/o Bioprocessing Tech- (21) International Application Number: nology Institute, 20 Biopolis Way, #06-01 Centros, Singa- PCT/SG2017/050509 pore 138668 (SG). TAN, Shao Weng Daniel; c/o Nation- (22) International Filing Date: al Cancer Centre Singapore, 11 Hospital Drive, Singapore 10 October 2017 (10.10.2017) 169610 (SG). IYER, Narayanan Gopalakrishna; c/o Na- tional Cancer Centre Singapore, 11 Hospital Drive, Singa- (25) Filing Language: English pore 169610 (SG). (26) Publication Language: English (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; (30) Priority Data: P.O. Box 1531, Robinson Road Post Office, Singapore 10201608481W 10 October 2016 (10.10.2016) SG 903031 (SG). (71) Applicants: SINGHEALTH SERVICES PTE LTD (81) Designated States (unless otherwise indicated, for every [SG/SG]; 31 Third Hospital Avenue, #03-03 Bowyer Block, kind of national protection available): AE, AG, AL, AM, Singapore 168632 (SG). AGENCY FOR SCIENCE, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, TECHNOLOGY AND RESEARCH; 1 Fusionopolis CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, Way, #20-10 Connexis North Tower, Singapore 138632 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (SG). HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (72) Inventors: LEUNG, Hau Wan; c/o Bioprocessing Tech- MG, MK, MN, MW, MX, MY MZ, NA, NG, NI, NO, NZ, = nology Institute, 20 Biopolis Way, Level 4 (Stem Cells) = — (54) Title: ANTI-CEACAM6 = = = 1400 .... 1200 = _ 1 = E 1000 = E 800 — = = 6 . 600 = 400 ANTIBODIES AND METHODS OF USE =., 4. X.7 Mean Tumor g . Volume Fig. 24 ± SEM Buffer ctrl -46465 G R6A04- M MAE H u-G R6A04 -rr GR6A04 = ,2 = — 200 = 0 4 Il (57) : The present invention CEACAM6, comprising (i) a heavy chain variable domain en c : N VHCDR2 having the amino acid © FYAMDY and (ii) a light chain IN VLCDR2 having the amino acid 0 ---. invention also relates to compositions *1: the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the 1-1 © antigen-binding protein, or antigen ei :4, a. 9 14 19 24 Study relates to an antigen sequence YINPYNDGTKYNEKFKG; variable domain comprising a VLCDR1 sequence GASIRES, and a VLCDR3 having comprising the antigen-binding protein, -binding fragment thereof. 29 Days -binding protein, comprising VHCDR1 34 a 39 and having or the or 44 a VHCDR3 having the amino acid sequence STARATPY- the MG 1.45- NAME (Isotype cal) an antigen-binding fragment thereof which binding to having the amino acid sequence GNTFTSYVMH; a amino acid sequence KSSQSLLWSVNQNSYLS, a amino acid sequence QHNHGSFLPYT. The present antigen-binding fragment thereof, methods of use of O [Continued on next page] WO 2018/070936 Al MIDEDIMOMOIDEIREEMOOMEIMIONOOROMEMOIS OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))